These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29391065)

  • 1. Comparison of lipid profiles and inflammation in pre- and post-menopausal women with cerebral infarction and the role of atorvastatin in such populations.
    Zhang J; Wang H; Yang S; Wang X
    Lipids Health Dis; 2018 Feb; 17(1):20. PubMed ID: 29391065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial.
    Kimura G; Kasahara M; Ueshima K; Tanaka S; Yasuno S; Fujimoto A; Sato T; Imamoto M; Kosugi S; Nakao K
    Clin Exp Nephrol; 2017 Jun; 21(3):417-424. PubMed ID: 27392909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atorvastatin Plus Metformin Confer Additive Benefits on Subjects with Dyslipidemia and Overweight/Obese via Reducing ROCK2 Concentration.
    Hao Z; Liu Y; Liao H; Zheng D; Xiao C; Li G
    Exp Clin Endocrinol Diabetes; 2016 Apr; 124(4):246-50. PubMed ID: 27123784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atorvastatin protects endothelium by decreasing asymmetric dimethylarginine in dyslipidemia rats.
    Zheng D; Liang Q; Zeng F; Mai Z; Cai A; Qiu R; Xu R; Li D; Mai W
    Lipids Health Dis; 2015 May; 14():41. PubMed ID: 25934565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
    Deguchi I; Horiuchi Y; Hayashi T; Sehara Y; Kato Y; Ohe Y; Fukuoka T; Maruyama H; Sano H; Nagamine Y; Tanahashi N
    J Stroke Cerebrovasc Dis; 2014 Sep; 23(8):2007-2011. PubMed ID: 25066602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST).
    Davidson MH; Rosenson RS; Maki KC; Nicholls SJ; Ballantyne CM; Mazzone T; Carlson DM; Williams LA; Kelly MT; Camp HS; Lele A; Stolzenbach JC
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1298-306. PubMed ID: 24743431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative studies on the effects of different doses of atorvastatin combined with aspirin on inflammatory cytokines and carotid plaques in patients with ischemic cerebrovascular disease.
    Deng Y; Zou W; Chen G; Shangguan S; Zhou F; Jiang W; Li X
    Int J Neurosci; 2019 Nov; 129(11):1133-1138. PubMed ID: 31232139
    [No Abstract]   [Full Text] [Related]  

  • 10. Differential Effects of Atorvastatin and Pitavastatin on Inflammation, Insulin Resistance, and the Carotid Intima-Media Thickness in Patients with Dyslipidemia.
    Nakagomi A; Shibui T; Kohashi K; Kosugi M; Kusama Y; Atarashi H; Shimizu W
    J Atheroscler Thromb; 2015; 22(11):1158-71. PubMed ID: 26084792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between bone mineral densities and serum lipid profiles of pre- and post-menopausal rural women in South Korea.
    Cui LH; Shin MH; Chung EK; Lee YH; Kweon SS; Park KS; Choi JS
    Osteoporos Int; 2005 Dec; 16(12):1975-81. PubMed ID: 16167087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.
    Goicoechea M; de Vinuesa SG; Lahera V; Cachofeiro V; Gómez-Campderá F; Vega A; Abad S; Luño J
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S231-5. PubMed ID: 17130267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial.
    Tsujita K; Sugiyama S; Sumida H; Shimomura H; Yamashita T; Yamanaga K; Komura N; Sakamoto K; Oka H; Nakao K; Nakamura S; Ishihara M; Matsui K; Sakaino N; Nakamura N; Yamamoto N; Koide S; Matsumura T; Fujimoto K; Tsunoda R; Morikami Y; Matsuyama K; Oshima S; Kaikita K; Hokimoto S; Ogawa H;
    J Am Coll Cardiol; 2015 Aug; 66(5):495-507. PubMed ID: 26227186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
    Bayés B; Granada ML; Lauzurica R; Pastor MC; Navarro M; Bonet J; Llopis MA; Romero R
    Transplant Proc; 2005 Nov; 37(9):3808-12. PubMed ID: 16386546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generic atorvastatin is as effective as the brand-name drug (LIPITOR
    Loch A; Bewersdorf JP; Kofink D; Ismail D; Abidin IZ; Veriah RS
    BMC Res Notes; 2017 Jul; 10(1):291. PubMed ID: 28716156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Niacin Therapy Increases High-Density Lipoprotein Particles and Total Cholesterol Efflux Capacity But Not ABCA1-Specific Cholesterol Efflux in Statin-Treated Subjects.
    Ronsein GE; Hutchins PM; Isquith D; Vaisar T; Zhao XQ; Heinecke JW
    Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):404-11. PubMed ID: 26681752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia.
    Maki KC; Bays HE; Dicklin MR; Johnson SL; Shabbout M
    J Clin Lipidol; 2011; 5(6):483-92. PubMed ID: 22108152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atorvastatin Combined Nitroglycerin Therapy Confer Additive Effects on Rabbits with Dyslipidemia.
    Yang F; Wang J; Li F; Cui L
    Exp Clin Endocrinol Diabetes; 2016 Jun; 124(6):367-71. PubMed ID: 27328402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term effects of low-dose atorvastatin on inflammatory status and lipid profiles in perimenopausal hypercholesterolemic, hypertriglyceridemic women.
    Ushiroyama T; Nosaka S; Ueki M
    Int J Cardiol; 2006 Oct; 113(1):66-75. PubMed ID: 16356567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dependent effects of atorvastatin on myocardial infarction.
    Barbarash O; Gruzdeva O; Uchasova E; Belik E; Dyleva Y; Karetnikova V
    Drug Des Devel Ther; 2015; 9():3361-8. PubMed ID: 26170622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.